Literature DB >> 18784570

Adrenal suppression following a single dose of etomidate for rapid sequence induction: a prospective randomized study.

Amy N Hildreth1, Vicente A Mejia, Robert A Maxwell, Philip W Smith, Benjamin W Dart, Donald E Barker.   

Abstract

BACKGROUND: The administration of etomidate for rapid sequence induction (RSI) has been linked to subsequent adrenocortical insufficiency in nontrauma patients. However, etomidate-related adrenocortical insufficiency has not been well studied in the trauma population.
PURPOSE: We performed a prospective, randomized, controlled study to assess the effect of one dose of etomidate for RSI on adrenal function and its clinical significance during and after resuscitation in trauma patients.
METHODS: Adult trauma patients admitted to our Level I trauma center requiring RSI were randomized to receive etomidate 0.3 mg/kg and succinylcholine 1 mg/kg (E group) or fentanyl 100 microg, midazolam 5 mg, and succinylcholine 1 mg/kg (FM group) for induction. A baseline serum cortisol level was drawn before RSI. Four to six hours after RSI, a postintubation serum cortisol level was drawn. An ACTH stimulation test was performed.
RESULTS: Thirty patients were enrolled: 18 E group patients and 12 FM group patients. No statistical difference was detected between the two groups with respect to age, injury severity score, and baseline serum cortisol. Mean serum cortisol levels were significantly lower in E group patients than in FM group patients 4 to 6 hours after intubation (18.2 vs. 27.8 mug/dL, p < 0.05). Change in serum cortisol between baseline and postintubation levels was different (-12.8 mg/dL +/- 9.6 microg/dL vs. 1.1 microg/dL +/- 7.6 microg/dL, p < 0.01). Patients in the E group had an average increase in cortisol after ACTH administration of 4.2 microg/dL +/- 4.9 microg/dL vs. 11.2 microg/dL +/- 6.1 microg/dL in the FM group, p < 0.001. Patients in the E group required longer ICU lengths of stay (mean, 6.3 days vs. 1.5 days, p < 0.05), more ventilator days (mean, 28 days vs. 17 days, p < 0.01), and longer hospital lengths of stay (mean, 11.6 days vs. 6.4 days, p < 0.01).
CONCLUSIONS: The use of etomidate for RSI in trauma patients led to chemical evidence of adrenocortical insufficiency and may have contributed to increased hospital and ICU lengths of stay and increased ventilator days. Further studies should be considered to evaluate the safety profile of this drug in trauma patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18784570     DOI: 10.1097/TA.0b013e31818255e8

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  51 in total

1.  [Emergency anesthesia, airway management and ventilation in major trauma. Background and key messages of the interdisciplinary S3 guidelines for major trauma patients].

Authors:  G Matthes; M Bernhard; K G Kanz; C Waydhas; M Fischbacher; M Fischer; B W Böttiger
Journal:  Unfallchirurg       Date:  2012-03       Impact factor: 1.000

2.  [Preclinical management of multiples injuries: S3 guideline].

Authors:  C Waydhas
Journal:  Unfallchirurg       Date:  2012-01       Impact factor: 1.000

3.  Is etomidate really that bad in septic patients?

Authors:  Fabio Moreira Andrade
Journal:  Intensive Care Med       Date:  2010-04-20       Impact factor: 17.440

Review 4.  [Results of studies in critical care medicine in the year 2009 : update].

Authors:  M Bernhard; G Marx; K Weismüller; C Lichtenstern; K Mayer; F M Brunkhorst; M A Weigand
Journal:  Anaesthesist       Date:  2010-05       Impact factor: 1.041

5.  Etomidate increases susceptibility to pneumonia in trauma patients.

Authors:  Karim Asehnoune; Pierre Joachim Mahe; Philippe Seguin; Samir Jaber; Boris Jung; Christophe Guitton; Nolwen Chatel-Josse; Aurelie Subileau; Anne Charlotte Tellier; Françoise Masson; Benoit Renard; Yannick Malledant; Corinne Lejus; Christelle Volteau; Véronique Sébille; Antoine Roquilly
Journal:  Intensive Care Med       Date:  2012-07-10       Impact factor: 17.440

6.  Carboetomidate: a pyrrole analog of etomidate designed not to suppress adrenocortical function.

Authors:  Joseph F Cotten; Stuart A Forman; Joydev K Laha; Gregory D Cuny; S Shaukat Husain; Keith W Miller; Hieu H Nguyen; Elizabeth W Kelly; Deirdre Stewart; Aiping Liu; Douglas E Raines
Journal:  Anesthesiology       Date:  2010-03       Impact factor: 7.892

Review 7.  Clinical and molecular pharmacology of etomidate.

Authors:  Stuart A Forman
Journal:  Anesthesiology       Date:  2011-03       Impact factor: 7.892

Review 8.  The effect of etomidate on adrenal function in critical illness: a systematic review.

Authors:  Stewart G Albert; Srividya Ariyan; Ayesha Rather
Journal:  Intensive Care Med       Date:  2011-03-04       Impact factor: 17.440

9.  Differential effects of etomidate and its pyrrole analogue carboetomidate on the adrenocortical and cytokine responses to endotoxemia.

Authors:  Ervin Pejo; Yan Feng; Wei Chao; Joseph F Cotten; Ri Le Ge; Douglas E Raines
Journal:  Crit Care Med       Date:  2012-01       Impact factor: 7.598

10.  Etomidate, adrenal function, and mortality in critically ill patients.

Authors:  Jacob E Sunshine; Steven Deem; Noel S Weiss; N David Yanez; Stephen Daniel; Katherine Keech; Marcia Brown; Miriam M Treggiari
Journal:  Respir Care       Date:  2013-04       Impact factor: 2.258

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.